12.88 USD
-0.03 (-0.23%)
12.81 USD
-0.07 (-0.54%)
Taking everything into account, AMRX scores 5 out of 10 in our fundamental rating. AMRX was compared to 191 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of AMRX get a neutral evaluation. Nothing too spectacular is happening here. A decent growth rate in combination with a cheap valuation! Better keep an eye on AMRX.
1. Profitability
1.1 Basic Checks
In the past year AMRX was profitable.
AMRX had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: AMRX reported negative net income in multiple years.
Each year in the past 5 years AMRX had a positive operating cash flow.
1.2 Ratios
AMRX has a better Return On Assets (0.16%) than 77.49% of its industry peers.
With an excellent Return On Invested Capital value of 10.43%, AMRX belongs to the best of the industry, outperforming 89.53% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for AMRX is below the industry average of 12.85%.
The last Return On Invested Capital (10.43%) for AMRX is above the 3 year average (7.98%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.16% | ||
| ROE | N/A | ||
| ROIC | 10.43% |
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
1.3 Margins
Looking at the Profit Margin, with a value of 0.20%, AMRX is in the better half of the industry, outperforming 77.49% of the companies in the same industry.
With an excellent Operating Margin value of 12.32%, AMRX belongs to the best of the industry, outperforming 85.34% of the companies in the same industry.
In the last couple of years the Operating Margin of AMRX has grown nicely.
With a Gross Margin value of 36.76%, AMRX perfoms like the industry average, outperforming 59.69% of the companies in the same industry.
AMRX's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.32% | ||
| PM (TTM) | 0.2% | ||
| GM | 36.76% |
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMRX is creating some value.
The number of shares outstanding for AMRX has been reduced compared to 1 year ago.
AMRX has more shares outstanding than it did 5 years ago.
AMRX has a better debt/assets ratio than last year.
2.2 Solvency
AMRX has an Altman-Z score of 1.91. This is not the best score and indicates that AMRX is in the grey zone with still only limited risk for bankruptcy at the moment.
AMRX's Altman-Z score of 1.91 is in line compared to the rest of the industry. AMRX outperforms 56.54% of its industry peers.
The Debt to FCF ratio of AMRX is 11.13, which is on the high side as it means it would take AMRX, 11.13 years of fcf income to pay off all of its debts.
AMRX's Debt to FCF ratio of 11.13 is fine compared to the rest of the industry. AMRX outperforms 78.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 11.13 | ||
| Altman-Z | 1.91 |
ROIC/WACC1
WACC10.39%
2.3 Liquidity
AMRX has a Current Ratio of 2.13. This indicates that AMRX is financially healthy and has no problem in meeting its short term obligations.
AMRX has a Current ratio of 2.13. This is in the lower half of the industry: AMRX underperforms 60.21% of its industry peers.
AMRX has a Quick Ratio of 1.42. This is a normal value and indicates that AMRX is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.42, AMRX is not doing good in the industry: 65.44% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.13 | ||
| Quick Ratio | 1.42 |
3. Growth
3.1 Past
AMRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.00%, which is quite impressive.
The Earnings Per Share has been growing by 10.63% on average over the past years. This is quite good.
AMRX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.73%.
Measured over the past years, AMRX shows a quite strong growth in Revenue. The Revenue has been growing by 11.43% on average per year.
EPS 1Y (TTM)25%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%6.25%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%11.68%
3.2 Future
AMRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.95% yearly.
The Revenue is expected to grow by 0.60% on average over the next years.
EPS Next Y40.55%
EPS Next 2Y27.65%
EPS Next 3Y26.95%
EPS Next 5Y11.95%
Revenue Next Year8.74%
Revenue Next 2Y7.7%
Revenue Next 3Y7.95%
Revenue Next 5Y0.6%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 17.17, the valuation of AMRX can be described as rather expensive.
AMRX's Price/Earnings ratio is rather cheap when compared to the industry. AMRX is cheaper than 83.77% of the companies in the same industry.
AMRX's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.77.
A Price/Forward Earnings ratio of 13.63 indicates a correct valuation of AMRX.
Based on the Price/Forward Earnings ratio, AMRX is valued cheaply inside the industry as 82.72% of the companies are valued more expensively.
AMRX is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.35, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.17 | ||
| Fwd PE | 13.63 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 86.39% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, AMRX is valued cheaply inside the industry as 84.82% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.12 | ||
| EV/EBITDA | 10.78 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of AMRX may justify a higher PE ratio.
AMRX's earnings are expected to grow with 26.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.42
PEG (5Y)1.62
EPS Next 2Y27.65%
EPS Next 3Y26.95%
5. Dividend
5.1 Amount
AMRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
12.88
-0.03 (-0.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners45.3%
Inst Owner Change6.11%
Ins Owners46.29%
Ins Owner Change-4.23%
Market Cap4.05B
Revenue(TTM)2.93B
Net Income(TTM)5.90M
Analysts82
Price Target14.28 (10.87%)
Short Float %3.42%
Short Ratio2.95
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.63%
Min EPS beat(2)21.21%
Max EPS beat(2)40.06%
EPS beat(4)3
Avg EPS beat(4)19.7%
Min EPS beat(4)-22.85%
Max EPS beat(4)40.37%
EPS beat(8)7
Avg EPS beat(8)26.2%
EPS beat(12)11
Avg EPS beat(12)30.21%
EPS beat(16)11
Avg EPS beat(16)19.73%
Revenue beat(2)0
Avg Revenue beat(2)-2.51%
Min Revenue beat(2)-4.6%
Max Revenue beat(2)-0.41%
Revenue beat(4)1
Avg Revenue beat(4)-2.13%
Min Revenue beat(4)-4.71%
Max Revenue beat(4)1.22%
Revenue beat(8)3
Avg Revenue beat(8)-0.67%
Revenue beat(12)7
Avg Revenue beat(12)0.45%
Revenue beat(16)8
Avg Revenue beat(16)-0.15%
PT rev (1m)5%
PT rev (3m)16.67%
EPS NQ rev (1m)1.44%
EPS NQ rev (3m)15.94%
EPS NY rev (1m)0.01%
EPS NY rev (3m)4.13%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.58%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.17 | ||
| Fwd PE | 13.63 | ||
| P/S | 1.38 | ||
| P/FCF | 17.12 | ||
| P/OCF | 12.35 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.78 |
EPS(TTM)0.75
EY5.82%
EPS(NY)0.95
Fwd EY7.34%
FCF(TTM)0.75
FCFY5.84%
OCF(TTM)1.04
OCFY8.09%
SpS9.34
BVpS-0.35
TBVpS-4.11
PEG (NY)0.42
PEG (5Y)1.62
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.16% | ||
| ROE | N/A | ||
| ROCE | 13.2% | ||
| ROIC | 10.43% | ||
| ROICexc | 11.26% | ||
| ROICexgc | 21.11% | ||
| OM | 12.32% | ||
| PM (TTM) | 0.2% | ||
| GM | 36.76% | ||
| FCFM | 8.06% |
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
ROICexc(3y)8.26%
ROICexc(5y)6.86%
ROICexgc(3y)18.59%
ROICexgc(5y)15.87%
ROCE(3y)10.57%
ROCE(5y)8.54%
ROICexgc growth 3Y25.12%
ROICexgc growth 5YN/A
ROICexc growth 3Y27.15%
ROICexc growth 5YN/A
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
F-Score7
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 11.13 | ||
| Debt/EBITDA | 4.36 | ||
| Cap/Depr | 37.95% | ||
| Cap/Sales | 3.11% | ||
| Interest Coverage | 1.67 | ||
| Cash Conversion | 54.45% | ||
| Profit Quality | 4008.53% | ||
| Current Ratio | 2.13 | ||
| Quick Ratio | 1.42 | ||
| Altman-Z | 1.91 |
F-Score7
WACC10.39%
ROIC/WACC1
Cap/Depr(3y)33.21%
Cap/Depr(5y)30.06%
Cap/Sales(3y)3.22%
Cap/Sales(5y)3.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%6.25%
EPS Next Y40.55%
EPS Next 2Y27.65%
EPS Next 3Y26.95%
EPS Next 5Y11.95%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%11.68%
Revenue Next Year8.74%
Revenue Next 2Y7.7%
Revenue Next 3Y7.95%
Revenue Next 5Y0.6%
EBIT growth 1Y26.75%
EBIT growth 3Y17.2%
EBIT growth 5YN/A
EBIT Next Year13.19%
EBIT Next 3Y10.22%
EBIT Next 5Y3.87%
FCF growth 1Y72%
FCF growth 3Y5.18%
FCF growth 5YN/A
OCF growth 1Y75.78%
OCF growth 3Y6.86%
OCF growth 5Y180.48%
AMNEAL PHARMACEUTICALS INC / AMRX FAQ
What is the fundamental rating for AMRX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AMRX.
What is the valuation status of AMNEAL PHARMACEUTICALS INC (AMRX) stock?
ChartMill assigns a valuation rating of 8 / 10 to AMNEAL PHARMACEUTICALS INC (AMRX). This can be considered as Undervalued.
How profitable is AMNEAL PHARMACEUTICALS INC (AMRX) stock?
AMNEAL PHARMACEUTICALS INC (AMRX) has a profitability rating of 6 / 10.
What is the financial health of AMNEAL PHARMACEUTICALS INC (AMRX) stock?
The financial health rating of AMNEAL PHARMACEUTICALS INC (AMRX) is 4 / 10.
What is the earnings growth outlook for AMNEAL PHARMACEUTICALS INC?
The Earnings per Share (EPS) of AMNEAL PHARMACEUTICALS INC (AMRX) is expected to grow by 40.55% in the next year.